拜耳进博会发布重磅产品

Core Insights - Bayer's Eylea 8mg (Aflibercept 8mg) was launched during the 8th China International Import Expo, approved by the National Medical Products Administration for the treatment of neovascular age-related macular degeneration (nAMD) [1] Industry Overview - The burden of nAMD is increasing, with the number of patients in China expected to rise from 4.5 million in 2020 to 8.8 million by 2050 [1] - Without timely intervention, approximately 75.7% of patients may progress to legal blindness within three years, significantly impacting personal quality of life and placing economic pressure on society [1] Product Launch - Eylea 8mg has already completed the first batch of patient injections in multiple provinces and cities across China [1]